Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Radiation Oncology
Would you consider partial breast irradiation in patients who otherwise meet PBI guidelines who have a pathogenic variant of CHEK2 or other moderate penetrance gene?
Related Questions
In the setting of recurrent breast cancer localized to the chest wall (no prior RT), do you allow concurrent abemaciclib or Enhertu with post-operative comprehensive chest wall irradiation?
How would you manage a patient with a negative axillary ultrasound but no sentinel lymph node evaluation at the time of lumpectomy for early-stage breast cancer?
Do you use traditional bony landmarks or contoured nodal volumes when designing breast and supraclavicular treatment fields?
In which scenarios do you stage breast cancer using CT and nuclear bone scans versus PET-CT?
How would you approach a patient that did not have preoperative axillary imaging and was found to have macromets on sentinel node biopsy, and on radiation planning scan has abnormal appearing nodes?
In the era of hypofractionation for breast cancer, how would you re-irradiate for these cases if recurrence develops years later?
When doing a tumor bed boost following whole breast irradiation, what do you typically use for CTV and PTV margin for photon and electron plans?
What is your approach to a tumor bed boost in early stage breast cancer patients with micrometastasis?
How long after surgery would you no longer offer PMRT for a patient who had pCR after neoadjuvant chemotherapy for stage IIB HER2+ breast cancer?
What fields would you treat for a postmastectomy patient with a single suspected small IMN node on MRI but no other criteria for PMRT and a negative SNB?
